Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Related News Articles

Blog
Public
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability careFor Randy Fagin…
Headline
The AHA’s social media toolkit for spreading awareness of the flu focuses on the beginning of fall and the availability of the flu vaccine for at-risk,…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Centers for Disease Control and Prevention Sept. 24 released its annual report on national sexually transmitted disease data, reporting a 9% decline in STD…
Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares insights into the organization’s bold approach to improving safety outcomes. From piloting…
Headline
The AHA Quest for Quality Prize honors hospitals and health systems committed to leadership and innovation in improving quality and advancing health. Learn how…